Abcam, ab240595, Anti-METTL3 antibody

Size: 100µL
Rabbit Polyclonal METTL3 antibody. Suitable for IP, WB and reacts with Human, Mouse samples. Cited in 18 publications. Immunogen corresponding to Synthetic Peptide within Human METTL3 aa 1-50.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human METTL3 aa 1-50. The exact immunogen used to generate this antibody is proprietary information.Q86U44

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 6.8 - 7.4 Preservative: 0.09% Sodium azide Constituents: Tris buffered saline, 0.1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The METTL3 protein also known as methyltransferase like 3 plays an important role in the modification of RNA. It is a component of the N6-adenosine-methyltransferase complex and is responsible for introducing the m6A mark on RNA. The molecular weight of METTL3 is approximately 70 kDa. This protein shows high expression in the human central nervous system and various cancer tissues indicating its broad significance.
Biological function summary
METTL3 contributes to the post-transcriptional regulation of gene expression by modulating m6A methylation. It functions as part of a complex with METTL14 and Wilms’ tumor 1-associating protein (WTAP) to execute this modification. The m6A mark influences RNA stability splicing export and translation affecting cellular processes significantly.
Pathways
METTL3 operates within critical pathways such as the mRNA stability and processing pathway. In these pathways METTL3 interacts with proteins like METTL14 and YTH domain-containing proteins which are important for m6A reader function. Together they regulate RNA processing events that influence cellular function and adaptation.
METTL3 associates strongly with cancer development and neurological disorders. In cancers alterations in METTL3 expression affect tumor progression and metastasis impacting oncogenes like MYC. In the realm of neurological disorders METTL3’s role in m6A modification affects RNA regulation aligning it with proteins like FTO which also participate in m6A demethylation processes. Understanding these connections highlights METTL3 as a potential target for therapeutic interventions.